

RET Inhibitor SPP86 is a Potential Candidate for the Clinical Treatment of Cutaneous Melanoma [Response to Letter]

Yuli Zhang^{1,2}, Haidong Liu¹, Kun Wang³, Juan Zheng⁴, Hong Luan¹, Ming Xin⁵

¹Department of Dermatology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China; ²Department of Endocrinology, The Second Hospital of Shandong University, Jinan, Shandong, People's Republic of China; ³Department of Endocrinology and Metabolism, Liaocheng, People's Hospital, Liaocheng, Shandong, People's Republic of China; ⁴Joint Laboratory for Translational Medicine Research, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China; ⁵The Key Laboratory of Molecular Pharmacology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China

Correspondence: Ming Xin, The Key Laboratory of Molecular Pharmacology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China, Email xinming137@163.com; Hong Luan, Department of Dermatology, Liaocheng People's Hospital, Liaocheng, Shandong, People's Republic of China, Email lcsrmyy@126.com

Dear editors

Thank you very much for your interest in our research and for your valuable feedback. We are grateful for your positive comments and appreciate the constructive suggestions you provided. Your input is essential to further improving our study.

Regarding your suggestion for in vivo experimental validation, we wholeheartedly agree and are actively pursuing related research. In fact, our team has already secured research funding and initiated in vivo experiments using a mouse melanoma model to assess the anti-tumor effects of SPP86. Upon completion of these experiments, we intend to publish the results as a separate paper, and we hope you will look forward to it.

We are also very interested in your suggestion to explore “synthetic lethality as a therapeutic strategy” and the potential of combining SPP86 with PARP1 inhibitors (eg, olaparib). We greatly appreciate this insightful recommendation, and it is an avenue we plan to explore in future studies.

Finally, we acknowledge that clinical treatment for melanoma remains a complex challenge. Our research in this area is ongoing, and we will continue working towards advancing our understanding and contributing to more effective therapeutic options for melanoma treatment.

Disclosure

The authors declare that there are no conflicts of interest in this communication.

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Drug Design, Development and Therapy 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Drug Design, Development and Therapy editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Drug Design, Development and Therapy

Dovepress
Taylor & Francis Group

Publish your work in this journal

Drug Design, Development and Therapy is an international, peer-reviewed open-access journal that spans the spectrum of drug design and development through to clinical applications. Clinical outcomes, patient safety, and programs for the development and effective, safe, and sustained use of medicines are a feature of the journal, which has also been accepted for indexing on PubMed Central. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/drug-design-development-and-therapy-journal>

<https://doi.org/10.2147/DDDT.S524526>